MCID: GLL008
MIFTS: 62

Gilles De La Tourette Syndrome malady

Categories: Genetic diseases, Rare diseases, Mental diseases

Aliases & Classifications for Gilles De La Tourette Syndrome

About this section

Aliases & Descriptions for Gilles De La Tourette Syndrome:

Name: Gilles De La Tourette Syndrome 52 11 23 24 25 70 13 68
Tourette Syndrome 52 11 23 48 24 25 49 12 50 38 2 39
Tourette Disorder 23 48 24 25
Gilles De La Tourette's Syndrome 48 24 25
Tourette's Disease 25 27
Maladie De Tics 23 24
Gts 25 70
Chronic Motor and Vocal Tic Disorder 25
Gilles De La Tourette's Disease 24
 
Growing Teratoma Syndrome 68
Motor-Verbal Tic Disorder 11
Tourette's Disorder 24
Tourette's Syndrome 48
Psychogenic Tics 11
Guinon's Disease 11
Td 25
Ts 25

Characteristics:

HPO:

64
gilles de la tourette syndrome:
Inheritance: autosomal dominant inheritance

Classifications:



External Ids:

OMIM52 137580
Disease Ontology11 DOID:11119
ICD1030 F95.2
ICD9CM32 307.23
MeSH39 D005879
NCIt45 C35078

Summaries for Gilles De La Tourette Syndrome

About this section
NIH Rare Diseases:48 Tourette syndrome is a complex neurological disorder that is characterized by repetitive, sudden, uncontrolled (involuntary) movements and sounds (vocalizations) called tics. Tourette syndrome is named for Georges Gilles de la Tourette, who first described this disorder in 1885. A variety of genetic and environmental factors likely play a role in causing Tourette syndrome. A small number of people with Tourette syndrome have been found to have mutations involving the SLITRK1 gene. The syndrome is believed to be linked to problems in certain areas of the brain, and the chemical substances (dopamine, serotonin, and norepinephrine) that help nerve cells talk to one another. It is estimated that about 1% of the population has Tourette syndrome. Many people with very mild tics may not be aware of them and never seek medical help. Tourette syndrome is four times as likely to occur in boys as in girls. Although Tourette syndrome can be a chronic condition with symptoms lasting a lifetime, most people with the condition experience their worst symptoms in their early teens, with improvement occurring in the late teens and continuing into adulthood. Last updated: 3/6/2016

MalaCards based summary: Gilles De La Tourette Syndrome, also known as tourette syndrome, is related to schizophrenia and low gamma-gt familial intrahepatic cholestasis, and has symptoms including stereotypy, neurological speech impairment and attention deficit hyperactivity disorder. An important gene associated with Gilles De La Tourette Syndrome is SLITRK1 (SLIT And NTRK Like Family Member 1), and among its related pathways are Neurotransmitter Clearance In The Synaptic Cleft and Biogenic Amine Synthesis. The drugs pergolide and pimozide have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and cortex, and related mouse phenotypes are homeostasis/metabolism and behavior/neurological.

Disease Ontology:11 A tic disorder that is characterized by multiple physical (motor) tics and at least one vocal (phonic) tic present for more than a year.

UniProtKB/Swiss-Prot:70 Gilles de la Tourette syndrome: Neurologic disorder manifested particularly by motor and vocal tics and associated with behavioral abnormalities.

MedlinePlus:38 If you have tourette syndrome, you make unusual movements or sounds, called tics. you have little or no control over them. common tics are throat-clearing and blinking. you may repeat words, spin, or, rarely, blurt out swear words. tourette syndrome is a disorder of the nervous system. it often occurs with other problems, such as attention deficit hyperactivity disorder (adhd) obsessive-compulsive disorder (ocd) anxiety depression the cause of tourette syndrome is unknown. it is more common in boys than girls. the tics usually start in childhood and may be worst in the early teens. many people eventually outgrow them. no treatment is needed unless the tics interfere with everyday life. excitement or worry can make tics worse. calm, focused activities may make them better. medicines and talk therapy may also help. nih: national institute of neurological disorders and stroke

CDC:2 Comprehensive Behavioral Intervention for Tics (CBIT) is a promising new treatment to reduce tic symptoms.

NINDS:49 Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. The first symptoms of TS are almost always noticed in childhood.

Genetics Home Reference:25 Tourette syndrome is a complex disorder characterized by repetitive, sudden, and involuntary movements or noises called tics. Tics usually appear in childhood, and their severity varies over time. In most cases, tics become milder and less frequent in late adolescence and adulthood.

OMIM:52 Tourette syndrome is a neurobehavioral disorder manifest particularly by motor and vocal tics and associated with... (137580) more...

Wikipedia:71 Tourette syndrome (TS or simply Tourette\'s), is a common neuropsychiatric disorder with onset in... more...

GeneReviews for NBK21138

Related Diseases for Gilles De La Tourette Syndrome

About this section

Diseases related to Gilles De La Tourette Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 98)
idRelated DiseaseScoreTop Affiliating Genes
1schizophrenia29.2ADRA1A, ADRA2A, CNTNAP2, COMT, DBH, DRD2
2low gamma-gt familial intrahepatic cholestasis12.0
3turner syndrome11.7
4glanzmann thrombasthenia11.5
5trichotillomania11.4
6tuberous sclerosis-110.9
7timothy syndrome10.9
8cholestasis, progressive familial intrahepatic 110.8
9cholestasis, benign recurrent intrahepatic10.8
10microcytic anemia10.7
11polycythemia10.7
12primary central nervous system lymphoma10.7
13albinism, oculocutaneous, type ib10.7
14tsc2 angiomyolipomas, renal, modifier of10.7
15huriez syndrome10.7
16virus-associated trichodysplasia spinulosa10.7
17basal cell carcinoma10.6DRD2, SLC6A3
18antisocial personality disorder10.6DRD2, DRD4, SLITRK1
19acute female pelvic peritonitis10.5DRD2, DRD4, SLC6A3
20splenic disease10.5DRD2, SLC6A3
21hyperglycemia10.5CNTNAP2, SLC6A3
22erysipelas10.5COMT, DRD2
23long qt syndrome-1110.5DRD2, SGCE
24tongue disease10.5COMT, DRD2, SLC6A3
25bladder mixed adenocarcinoma10.5DBH, DRD2, SLC6A3
26obsessive-compulsive disorder10.5
27polycystic kidney disease 210.5DBH, DRD2, SLC6A3
28asperger syndrome10.5BTBD9, DRD2, SLC6A3
29adult spinal cord ependymoma10.4DRD2, DRD4
30tic disorder10.4
31vulvar disease10.4COMT, DBH, DRD2
32cocaine dependence10.4DRD2, DRD5, SLC6A3
33parkinsonism-dystonia, infantile10.4COMT, DRD2, SLC6A3
34segmental dystonia10.4DRD2, DRD5, SGCE
35adult brain stem glioma10.4DRD5, SGCE, SLC6A3
36intermittent explosive disorder10.4DRD2, DRD4, DRD5, SLC6A3
37phlegmonous dacryocystitis10.4COMT, DRD2, DRD4, SLC6A3
38chronic cervicitis10.4COMT, DRD2, DRD4, SLC6A3
39purpura10.4COMT, DRD2, DRD4
40enthesopathy10.4COMT, DRD2, DRD4, SLC6A3
41avoidant personality disorder10.4COMT, DRD2, DRD4, SLC6A3
42maternal uniparental disomy of chromosome 1310.4COMT, DBH, DRD2, DRD4
43mutism10.3CNTNAP2, DRD2
44chronic tic disorder10.3
45acquired night blindness10.3ADRA1A, ADRA2A
46hemorrhagic cystitis10.2COMT, DBH, DRD2, DRD4, SLC6A3
47dystonia10.2
48colorectal cancer10.2
49albinism, oculocutaneous, type v10.2DRD2, DRD4, DRD5
50pervasive developmental disorder10.2ADRA2A, COMT, DRD4, DRD5, SLC6A3

Graphical network of the top 20 diseases related to Gilles De La Tourette Syndrome:



Diseases related to gilles de la tourette syndrome

Symptoms & Phenotypes for Gilles De La Tourette Syndrome

About this section

Symptoms by clinical synopsis from OMIM:

137580

Clinical features from OMIM:

137580

Human phenotypes related to Gilles De La Tourette Syndrome:

 64 (show all 16)
id Description HPO Frequency HPO Source Accession
1 stereotypy64 typical (50%) HP:0000733
2 neurological speech impairment64 typical (50%) HP:0002167
3 attention deficit hyperactivity disorder64 typical (50%) HP:0007018
4 autism64 occasional (7.5%) HP:0000717
5 obsessive-compulsive behavior64 occasional (7.5%) HP:0000722
6 chorea64 occasional (7.5%) HP:0002072
7 migraine64 occasional (7.5%) HP:0002076
8 incoordination64 occasional (7.5%) HP:0002311
9 sleep disturbance64 occasional (7.5%) HP:0002360
10 neoplasm of the nervous system64 occasional (7.5%) HP:0004375
11 self-injurious behavior64 occasional (7.5%) HP:0100716
12 aggressive behavior64 HP:0000718
13 self-mutilation64 HP:0000742
14 echolalia64 HP:0010529
15 motor tics64 HP:0100034
16 phonic tics64 HP:0100035

UMLS symptoms related to Gilles De La Tourette Syndrome:


athetosis, back pain, headache, pain, sciatica, seizures, sleep disturbances, syncope, tremor, chronic pain, hyperexplexia, vertigo/dizziness, stammering/stuttering/tic, sleeplessness

MGI Mouse Phenotypes related to Gilles De La Tourette Syndrome according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053768.5ADRA1A, ADRA2A, BTBD9, COMT, DBH, DRD2
2MP:00053867.8ADRA1A, ADRA2A, BTBD9, CNTNAP2, COMT, DBH
3MP:00036317.4ADRA2A, BTBD9, CNTNAP2, COMT, DBH, DRD2

Drugs & Therapeutics for Gilles De La Tourette Syndrome

About this section

Drugs for Gilles De La Tourette Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 144)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
ClonidineapprovedPhase 42264205-90-72803
Synonyms:
1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro- (9CI)
2,6-Dichloro-N-2-imidazolidinylidenebenzenamine
2,6-dichloro-N-(2-imidazolidinylidene)aniline
2,6-dichloro-N-2-imidazolidinylidenebenzenamide
2,6-dichloro-N-imidazolidin-2-ylideneaniline
2-((2,6-Dichlorophenyl)imino)imidazolidine
2-(2,6-Dichloroanilino)-1,3-diazacyclopentene-(2)
2-(2,6-Dichloroanilino)-2-imidazoline
2-(2,6-Dichlorophenylamino)-2-imidazoline
2-(2,6-Dichlorophenylimino)imidazolidine
2-Imidazoline, 2-(2,6-dichloroanilino)- (7CI,8CI)
2-[(2,6-Dichlorophenyl)imino]imidazoline
2-[(2,6-dichlorophenyl)imino]-2-imidazoline
4205-90-7
4205-91-8 (mono-hydrochloride)
57066-25-8
734571A
AB00514634
AC1L1EI5
AC1Q3K6V
AKOS001595470
Adesipress
BIDD:GT0547
BPBio1_000040
BRD-K98530306-001-02-1
BRD-K98530306-003-05-0
BSPBio_000036
BSPBio_001588
BSPBio_002055
Bio1_000470
Bio1_000959
Bio1_001448
Bio2_000308
Bio2_000788
C9H9Cl2N3
CAS-4205-91-8
CATAPRES-TTS-1
CATAPRES-TTS-2
CATAPRES-TTS-3
CCRIS 7787
CHEBI:3757
CHEBI:46632
CHEMBL134
CID2803
Catapres
Catapres- TTS
Catapres-TTS
Catapresan
Catapressan
Catarpres
Catarpres-TTS
Catarpres-TTS (TN)
Catarpresan
Chlofazoline
Chlornidinum
Clofenil
Clonidin
Clonidina
Clonidina [INN-Spanish]
Clonidine (JAN/USAN/INN)
Clonidine HCl
Clonidine [USAN:BAN:INN]
Clonidinhydrochlorid
Clonidinum
Clonidinum [INN-Latin]
Clonistada
Clopheline
D00281
DB00575
DB07566
DivK1c_000774
 
Dixarit
Duraclon
Duraclont
EINECS 224-119-4
Gemiton
HMS1361P10
HMS1791P10
HMS1989P10
HMS2089G11
HSDB 3040
Hemiton
IDI1_000774
IDI1_034058
Ipotensium
Isoglaucon
KBio1_000774
KBio2_000308
KBio2_001821
KBio2_002876
KBio2_004389
KBio2_005444
KBio2_006957
KBio3_000615
KBio3_000616
KBio3_001275
KBioGR_000308
KBioGR_001572
KBioSS_000308
KBioSS_001821
Klofelin
Klofenil
L000193
LS-79606
Lopac-C-7897
Lopac0_000268
M 5041T
M-5041T
MolPort-001-779-668
MolPort-005-932-374
N-(2,6-Dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine
NCGC00015268-01
NCGC00015268-02
NCGC00015268-08
NCGC00024734-01
NCGC00024734-02
NCGC00024734-03
NCGC00024734-04
NCGC00024734-05
NCGC00179680-01
NINDS_000774
Prestwick0_000248
Prestwick1_000248
Prestwick2_000248
Prestwick3_000248
SKF 34427
SPBio_001233
SPBio_002255
ST 155BS
ST-155-BS
ST-155BS
Spectrum2_001187
Spectrum3_000358
Spectrum4_000956
Spectrum5_000759
Spectrum_001341
T171
Tenso-Timelets
Tocris-0690
UNII-MN3L5RMN02
ZINC00896484
clonidine
nchembio.79-comp11
nchembio705-10
2
Aripiprazoleapproved, investigationalPhase 4, Phase 3353129722-12-960795
Synonyms:
129722-12-9
24-29-3
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-2(1H)-quinolinone
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone
7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril
7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one
7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one
AC-1554
AC1L1TXZ
AC1Q3T38
ALKS-9070
Abilify
Abilify (TN)
Abilify Discmelt
Abilitat
Aripiprazol
Aripiprazole
Aripiprazole (JAN/USAN/INN)
Aripiprazole [USAN]
Aripiprazolum
Aripirazole
Arpizol
Asprito|
BMS-337039
Bio-0004
Bristol-Myers Squibb brand of aripiprazole
C094645
C12564
C23H27Cl2N3O2
CHEBI:31236
CHEMBL1112
CID60795
CPD000466383
 
D01164
DB01238
Discmelt
FT-0082572
HMS2051I18
HMS2089M20
HMS2093F22
HSDB 7320
KS-1030
L001339
LS-142666
MLS000759517
MLS001165779
MLS001195621
MLS001424078
MolPort-002-885-808
MolPort-003-844-657
NCGC00159510-02
NCGC00159510-03
OPC 31
OPC-14597
OPC-31
Opc 14597
Otsuka brand of aripiprazole
Pripiprazole
S06-0010
SAM001246750
SMR000466383
STK625160
TL8000707
TL80090184
UNII-82VFR53I78
aripiprazol
aripiprazole
aripiprazolum
||OPC 14597
3
DopamineapprovedPhase 4, Phase 3, Phase 1, Phase 2375951-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
4
Olanzapineapproved, investigationalPhase 4395132539-06-14585
Synonyms:
132539-06-1
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methyl-1-piperazinyl)-10 H -thieno[2,3- b ] [1,5]benzodiazepine
2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine
AC-665
AC1L1IHS
AKOS000282888
ALKS-7921
BIDD:GT0332
BIDD:PXR0138
Bio-0169
C07322
C076029
C17H20N4S
CHEBI:7735
CHEMBL715
CID4585
CPD000466345
D00454
DB00334
Eli Lilly brand of olanzapine
HMS2051H05
HMS2089M04
HMS2093I04
I06-0784
InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H
InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
Jsp001969
KS-1090
L000455
L005958
LS-152313
LY 170053
LY-170052
 
LY-170053
Lanzac
Lilly brand of olanzapine
MLS000759457
MLS001165781
MLS001195646
MLS001424057
Midax
MolPort-002-885-845
MolPort-003-666-569
MolPort-005-977-341
NCGC00096077-01
NCGC00096077-03
NCGC00096077-04
Olansek
Olanzapin
Olanzapina
Olanzapine
Olanzapine (JAN/USAN/INN)
Olanzapine (OLA)
Olanzapine [USAN:INN]
Olanzapinum
S2493_Selleck
SAM001246652
SMR000466345
SPECTRUM1505024
STK634338
Symbyax
TL8000772
UNII-N7U69T4SZR
Zalasta
Zydis
Zyprexa
Zyprexa (TN)
Zyprexa Intramuscular
Zyprexa Velotab
Zyprexa Zydis
olanzapina
olanzapine
olanzapinum
5
Guanfacineapproved, investigationalPhase 4, Phase 35629110-47-23519
Synonyms:
29110-47-2
29110-48-3 (mono-hydrochloride)
AC1L1G4B
BPBio1_000415
BRD-K32830106-003-03-0
BSPBio_000377
C07037
C9H9Cl2N3O
CAS-29110-48-3
CHEMBL862
CID3519
D08031
DB01018
EINECS 249-442-8
Estulic
Estulic (TN)
G1043_SIGMA
GUANFACINE
Guanfacina
Guanfacina [INN-Spanish]
Guanfacine (INN)
Guanfacine Monohydrochloride
Guanfacine [INN:BAN]
Guanfacinum
 
Guanfacinum [INN-Latin]
Intuniv
L000286
L013430
LS-174236
Lon798
Lopac-G-1043
Lopac0_000519
MolPort-003-941-447
N (Aminoiminomethyl)-2,6-dichlorobenzeneacetamide
N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide
NCGC00015469-01
NCGC00015469-02
NCGC00015469-06
NCGC00024950-01
NCGC00024950-02
NCGC00024950-03
Prestwick0_000339
Prestwick1_000339
Prestwick2_000339
Prestwick3_000339
SPBio_002298
SPD 503
Tocris-1030
UNII-30OMY4G3MK
ZINC03872738
6PiracetamapprovedPhase 41707491-74-9
7
Fluvoxamineapproved, investigationalPhase 44854739-18-33404, 5324346
Synonyms:
(1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-(2-aminoethyl)oxime
2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine
2-[({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene}amino)oxy]ethanamine
54739-18-3
61718-82-9 (maleate)
AB00514702
AC-1679
AC1NT50J
AC1Q4JNU
AR-1D5360
BIDD:GT0609
BPBio1_001199
BRD-K53517854-050-03-2
BSPBio_001089
C07571
C15H21F3N2O2
CHEBI:5138
CHEMBL814
CID5324346
D07984
DB00176
Dumirox
Dumyrox
Faverin
 
Fevarin
Floxyfral
Fluvoxamina
Fluvoxamina [INN-Spanish]
Fluvoxamine
Fluvoxamine (INN)
Fluvoxamine [INN:BAN]
Fluvoxamine maleate
Fluvoxamine-CR
Fluvoxaminum
Fluvoxaminum [INN-Latin]
I01-8382
LS-101999
Lopac0_000495
Luvox
Maveral
MolPort-005-943-374
NCGC00018193-07
NCGC00021870-04
NCGC00021870-05
Prestwick2_000995
Prestwick3_000995
UNII-O4L1XPO44W
fluvoxamine
fluvoxamine-CR
8
HaloperidolapprovedPhase 414152-86-83559
Synonyms:
1-(3-P-Fluorobenzoylpropyl)-4-P-chlorophenyl-4-hydroxypiperidine
4'-Fluoro-4-(4-(P-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone
4'-Fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone
4-(4-(Para-chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone
4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one
5-21-02-00377 (Beilstein Handbook Reference)
52-86-8
AB00052008
AC-19691
AC1L1G7K
AC1Q77Z0
AKOS000280660
ALDO
Aldo
Aloperidin
Aloperidol
Aloperidolo
Aloperidolo [DCIT]
Aloperidolo [Italian]
Aloperidon
Apo-Haloperidol
BIDD:GT0128
BPBio1_000144
BPBio1_001231
BRD-K67783091-001-04-8
BRD-K67783091-001-05-5
BRN 0331267
BSPBio_000130
BSPBio_002096
Bio-0705
Biomol-NT_000035
Bioperidolo
Brotopon
C01814
C21H23ClFNO2
CAS-52-86-8
CCRIS 1630
CHEBI:5613
CHEMBL54
CID3559
D00136
D006220
DB00502
DivK1c_000654
Dozic
Dozix
EINECS 200-155-6
EU-0100583
Einalon S
Eukystol
Fortunan
Galoperidol
H 1512
H0912
H1512_SIGMA
HMS1568G12
HMS1920D03
HMS2089M15
HMS2091J09
HMS502A16
HSDB 3093
Haldol
Haldol Decanoate
Haldol La
Haldol Solutab
Halidol
Halojust
Halol
Halopal
Haloperido
Haloperidol (JP15/USP)
Haloperidol (JP15/USP/INN)
Haloperidol Decanoate
Haloperidol Intensol
Haloperidol Lactate
Haloperidol [USAN:INN:BAN:JAN]
Haloperidolum
Haloperidolum [INN-Latin]
Halopidol
Halopoidol
Halosten
I14-13404
I14-14165
IDI1_000654
 
KBio1_000654
KBio2_001341
KBio2_002390
KBio2_003909
KBio2_004958
KBio2_006477
KBio2_007526
KBio3_001316
KBio3_002869
KBioGR_000980
KBioGR_002390
KBioSS_001341
KBioSS_002395
Keselan
L000288
LS-48311
Lealgin Compositum
Lealgin compositum
Linton
Lopac-H-1512
Lopac0_000583
MLS000028450
MLS001146904
McN-JR-1625
Mixidol
MolPort-000-883-311
NCGC00015500-01
NCGC00015500-02
NCGC00015500-06
NCGC00015500-14
NCGC00016234-01
NCGC00023875-02
NCGC00023875-04
NCGC00023875-05
NCGC00023875-06
NCGC00023875-07
NCGC00023875-08
NCGC00023875-09
NINDS_000654
NSC 170973
NSC 615296
NSC170973
NSC615296
Novo-Peridol
Oprea1_509923
Pekuces
Peluces
Peridol
Pernox
Pms Haloperidol
Prestwick0_000115
Prestwick1_000115
Prestwick2_000115
Prestwick3_000115
Prestwick_250
Probes1_000255
Probes2_000296
QTL1_000042
R 1625
R-1625
S1920_Selleck
SMR000058303
SPBio_001236
SPBio_002069
SPECTRUM1500325
Serenace
Serenase
Serenelfi
Sernas
Sernel
Sigaperidol
Spectrum2_001268
Spectrum3_000448
Spectrum4_000570
Spectrum5_000788
Spectrum_000861
Tocris-0931
UNII-J6292F8L3D
Ulcolind
Uliolind
Vesalium
WLN: T6NTJ A3VR DF& DQ DR DG
cMAP_000037
gamma-(4-(P-Chlorophenyl)-4-hydroxpiperidino)-P-fluorbutyrophenone
haloperidol
9
Fluoxetineapproved, vet_approvedPhase 423554910-89-33386
Synonyms:
(+) or (-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine
(+) or (-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamine
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine
(+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
(+/-)-Fluoxetine
(+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
(+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine
(+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine
(+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]
(+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine
3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
52341-67-0
54910-89-3
57226-07-0
59333-67-4 (hydrochloride)
AB00053774
AC-14564
AC1L1FTH
AKOS003663021
Adofen
Animex-On
BPBio1_000354
BPBio1_000509
BRD-A31159102-001-01-9
BRD-A31159102-003-05-6
BSPBio_000461
BSPBio_003375
Bio-0787
Biomol-NT_000152
C17H18F3NO
CHEBI:5118
CHEMBL41
CID3386
D00326
DB00472
Deprex
DivK1c_006819
Eufor
Floxetine
Fluctin
Fluoxeren
Fluoxetin
Fluoxetina
Fluoxetina [INN-Spanish]
Fluoxetina [Spanish]
Fluoxetine (TN)
Fluoxetine (USAN/INN)
Fluoxetine Hcl
Fluoxetine Hydrochloride
Fluoxetine [USAN:INN:BAN]
Fluoxetinum
 
Fluoxetinum [INN-Latin]
Fluoxétine
Fluval
Fontex
Foxetin
HMS2090H14
KBio1_001763
KBio2_002159
KBio2_004727
KBio2_007295
KBio3_002595
KBioGR_001166
KBioSS_002159
L000931
LS-31040
Lilly-110140
Lopac0_000558
Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine
Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine
MolPort-001-683-482
N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine
NCGC00015428-10
NCGC00024879-03
NCGC00024879-04
NSC283480
Portal
Prestwick0_000511
Prestwick1_000511
Prestwick2_000511
Prestwick3_000511
Prozac
Prozac Weekly
Pulvules
Reconcile
Reneuron
SPBio_001815
SPBio_002382
STK734483
Sarafem
SpecPlus_000723
Spectrum2_001658
Spectrum3_001648
Spectrum4_000613
Spectrum5_001518
Spectrum_001679
TL8003595
UNII-01K63SUP8D
dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
fluoxetine
fluoxetine (Prozac)
nchembio.534-comp2
10
Riluzoleapproved, investigationalPhase 4631744-22-55070
Synonyms:
1744-22-5
2-Amino-6-(trifluoromethoxy)-benzothiazole
2-Amino-6-(trifluoromethoxy)benzothiazole
2-Amino-6-trifluoro- methoxybenzothiazole
2-amino-6-(trifluoromethoxy)-1,3-benzothiazole
2-amino-6-(trifluoromethoxy)benzo[d]thiazole
2-amino-6-(trifluoromethoxyl)benzothiazole
2-amino-6-trifluoromethoxybenzothiazole
6-(trifluoromethoxy)-1,3-benzothiazol-2-amine
6-(trifluoromethoxy)benzo[d]thiazol-2-amine
6-Trifluoromethoxy-benzothiazol-2-ylamine
6-trifluoromethoxybenzothiazole-2-yl-amine
AC-730
AC1L1JJL
AC1Q530H
AKOS000265071
ALBB-006046
Amino-2 trifluoromethoxy-6 benzothiazole
Amino-2 trifluoromethoxy-6 benzothiazole [French]
BB_SC-4839
BF-37
BIDD:GT0055
BPBio1_000037
BPBio1_000837
BRD-K21283037-001-02-5
BRD-K21283037-003-03-9
BSPBio_000033
Bio1_000416
Bio1_000905
Bio1_001394
Biomol-NT_000245
C07937
C8H5F3N2OS
CHEMBL744
CID5070
D00775
DB00740
EU-0101064
FT-0082997
HMS1773G08
HMS2089O19
HMS2094G07
I01-2084
LS-40688
 
Lopac-R-116
Lopac0_001064
MLS000069369
MolPort-000-151-262
NCGC00015882-01
NCGC00015882-02
NCGC00015882-03
NCGC00015882-07
NCGC00015882-11
NCGC00023141-02
NCGC00023141-04
NCGC00023141-05
NCGC00023141-06
PK-26124
PK-26124, RP-54274, Rilutek, Riluzole
Prestwick-03A08
Prestwick0_000167
Prestwick1_000167
Prestwick2_000167
Prestwick3_000167
R-116
R116_SIGMA
RP 54274
RP-54274
Rilutek
Rilutek (TN)
Riluzol
Riluzol [INN-Spanish]
Riluzole
Riluzole (JAN/USAN/INN)
Riluzole HCl
Riluzole [USAN:INN]
Riluzolum
Riluzolum [INN-Latin]
S1614_Selleck
SMR000058231
SPBio_000599
SPBio_001954
STK503686
Spectrum2_000550
Tocris-0768
UNII-7LJ087RS6F
ZERO/001785
ZINC00006481
riluzole
11
GalantamineapprovedPhase 4105357-70-09651, 908828, 9651
Synonyms:
(-)-Galanthamine
(4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol
1551-02-6
1953-04-4
1dx6
1qti
357-70-0
4-27-00-02184 (Beilstein Handbook Reference)
736-79-8
AC-20240
AC1L1TIM
BIDD:GT0517
BPBio1_000480
BRD-K49481516-004-03-5
BRD-K49481516-004-04-3
BRN 0093736
BSPBio_000436
BSPBio_003416
C08526
CHEBI:42944
CHEMBL659
CID9651
D04292
DivK1c_000590
GNT
Galantamin
Galantamina
Galantamina [INN-Spanish]
Galantamine
Galantamine (USAN/INN)
Galantamine [USAN:INN]
Galantaminum
Galantaminum [INN-Latin]
Galanthamine
Galanthamine hydrobromide
Galanthaminum
 
HMS2089H03
HSDB 7361
IDI1_000590
InChI=1/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1
Jilkon
KBio1_000590
KBio2_001751
KBio2_004319
KBio2_006887
KBio3_002636
KBioGR_001417
KBioSS_001751
LS-71039
Lycoremin
Lycoremine
MolPort-002-521-885
NCGC00024731-02
NINDS_000590
NSC 100058
Prestwick0_000588
Prestwick1_000588
Prestwick2_000588
Prestwick3_000588
Probes1_000055
Probes2_000395
Razadyne ER
Reminyl
Reminyl (TN)
SDCCGMLS-0066737.P001
SMP1_000131
SPBio_002655
STOCK1N-46108
Spectrum3_001738
Spectrum4_000839
Spectrum5_001673
Spectrum_001271
UNII-0D3Q044KCA
galanthamine
12Adrenergic alpha-AgonistsPhase 4, Phase 31625
13AnalgesicsPhase 411287
14Adrenergic alpha-2 Receptor AgonistsPhase 4, Phase 3911
15Central Nervous System DepressantsPhase 4, Phase 3, Phase 1, Phase 212806
16Adrenergic AgonistsPhase 4, Phase 32877
17Antihypertensive AgentsPhase 4, Phase 34095
18Autonomic AgentsPhase 49774
19SympatholyticsPhase 4555
20Adrenergic AgentsPhase 4, Phase 3, Phase 25140
21Peripheral Nervous System AgentsPhase 422776
22Neurotransmitter AgentsPhase 4, Phase 3, Phase 1, Phase 217734
23Dopamine AntagonistsPhase 4, Phase 3, Phase 1, Phase 21083
24Cytochrome P-450 Enzyme InhibitorsPhase 43822
25Cytochrome P-450 CYP2D6 InhibitorsPhase 4716
26
SerotoninPhase 4, Phase 2356650-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
27Serotonin AgentsPhase 4, Phase 23102
28Serotonin Uptake InhibitorsPhase 41570
29Cytochrome P-450 CYP1A2 InhibitorsPhase 4553
30Neurotransmitter Uptake InhibitorsPhase 4, Phase 23464
31Haloperidol decanoatePhase 4141
32Gastrointestinal AgentsPhase 48109
33Dopamine AgentsPhase 4, Phase 3, Phase 1, Phase 23759
34Protective AgentsPhase 4, Phase 3, Phase 27190
35Antipsychotic AgentsPhase 4, Phase 3, Phase 1, Phase 22359
36Excitatory Amino AcidsPhase 41297
37Excitatory Amino Acid AntagonistsPhase 41282
38AntiemeticsPhase 43888
39Excitatory Amino Acid AgonistsPhase 420
40Psychotropic DrugsPhase 4, Phase 3, Phase 1, Phase 26279
41Neuroprotective AgentsPhase 4, Phase 31672
42Anti-Anxiety AgentsPhase 41816
43Tranquilizing AgentsPhase 4, Phase 3, Phase 1, Phase 24164
44AnticonvulsantsPhase 4, Phase 3, Phase 1, Phase 22620
45Antidepressive AgentsPhase 42666
46EtiracetamPhase 4200
47Antidepressive Agents, Second-GenerationPhase 41287
48Nootropic AgentsPhase 4701
49Cholinergic AgentsPhase 43846
50Cholinesterase InhibitorsPhase 4570

Interventional clinical trials:

(show top 50)    (show all 125)
idNameStatusNCT IDPhase
1Study of Clonidine on Sleep Architecture in Children With Tourette's Syndrome (TS) and Comorbid ADHDUnknown statusNCT00152750Phase 4
2Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic NeurotransmissionCompletedNCT01018056Phase 4
3Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's DisorderCompletedNCT00241176Phase 4
4Comparison of Keppra and Clonidine in the Treatment of TicsCompletedNCT00370838Phase 4
5Guanfacine in Children With Tic DisordersCompletedNCT01547000Phase 4
6Treatment of Obsessive-Compulsive DisorderCompletedNCT00000373Phase 4
7Safety Study of Galantamine in Tic DisordersTerminatedNCT00226824Phase 4
8A Randomized, Placebo-Controlled, Tourette Syndrome Study.CompletedNCT00206323Phase 3
9An Open-Label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.CompletedNCT00206336Phase 3
10Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity DisorderCompletedNCT00004376Phase 3
11Safety & Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's DisorderCompletedNCT01416441Phase 3
12Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's DisorderCompletedNCT01418352Phase 3
13Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's DisorderCompletedNCT01418339Phase 3
14Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's DisorderCompletedNCT01727700Phase 3
15Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's DisorderCompletedNCT01727713Phase 3
16Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's DisorderCompletedNCT00706589Phase 3
17Cognitive Behavior Therapy and Habit Reversal Training for the Treatment of Chronic Tic Disorders in ChildrenCompletedNCT00218777Phase 2, Phase 3
18Phase III Study of 5LGr to Treat Tic DisorderCompletedNCT01501695Phase 3
19Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg)CompletedNCT00001768Phase 3
20Pallidal Stimulation and Gilles de la Tourette SyndromeActive, not recruitingNCT00478842Phase 3
21Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette SyndromeTerminatedNCT00681863Phase 3
22Optimising Anterior Pallidal Deep Brain Stimulation for Tourette's SyndromeUnknown statusNCT02112253Phase 1, Phase 2
23Cannabis for Inflammatory Bowel DiseaseUnknown statusNCT01040910Phase 1, Phase 2
24Thalamic Deep Brain Stimulation for Tourette SyndromeCompletedNCT00311909Phase 2
25Ecopipam Treatment of Tourette SyndromeCompletedNCT01244633Phase 1, Phase 2
26VoIP Delivered Behavior Therapy for Tourette SyndromeCompletedNCT02247206Phase 2
27A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette SyndromeCompletedNCT02217007Phase 2
28N-acetylcysteine (NAC) for Children With Tourette SyndromeCompletedNCT01172288Phase 2
29Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette's SyndromeCompletedNCT00529308Phase 2
30A Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Tourette SyndromeCompletedNCT01647269Phase 2
31Subthalamic Stimulation in Tourette's SyndromeCompletedNCT02619084Phase 2
32Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's DisorderCompletedNCT01904773Phase 2
33Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic DisorderCompletedNCT00231985Phase 2
34Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette SyndromeCompletedNCT00004393Phase 2
35Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette SyndromeCompletedNCT00004652Phase 2
36Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV CriteriaCompletedNCT00558467Phase 2
37Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's DisorderCompletedNCT01585207Phase 1, Phase 2
38Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette SyndromeRecruitingNCT02679079Phase 2
39Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 YearsActive, not recruitingNCT02102698Phase 2
40Safety and Efficacy Study of NBI-98854 in Adults With Tourette SyndromeActive, not recruitingNCT02581865Phase 2
41Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette SyndromeEnrolling by invitationNCT02879578Phase 2
42FAAH Inhibitor Trial for Adults With Tourette SyndromeSuspendedNCT02134080Phase 2
43Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's SyndromeTerminatedNCT01475383Phase 2
44Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette SyndromeTerminatedNCT01043549Phase 2
45A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette's SyndromeWithdrawnNCT01133353Phase 2
46A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome (TS)CompletedNCT02674321Phase 1
47Developing Cognitive Training for Tourette SyndromeCompletedNCT01440023Phase 1
48Open-Trial of EPI-743 for Adults With Tourette SyndromeCompletedNCT01719523Phase 1
49High Frequency Stimulation of the GPi or Thalamus in Tourette's SyndromeCompletedNCT00139308Phase 1
50Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette SyndromeCompletedNCT02256475Phase 1

Search NIH Clinical Center for Gilles De La Tourette Syndrome

Inferred drug relations via UMLS68/NDF-RT46:


Cochrane evidence based reviews: tourette syndrome

Genetic Tests for Gilles De La Tourette Syndrome

About this section

Genetic tests related to Gilles De La Tourette Syndrome:

id Genetic test Affiliating Genes
1 Tourette Syndrome27 24 SLITRK1

Anatomical Context for Gilles De La Tourette Syndrome

About this section

MalaCards organs/tissues related to Gilles De La Tourette Syndrome:

36
Brain, Eye, Cortex, Globus pallidus, Thalamus, Colon, Bone

Publications for Gilles De La Tourette Syndrome

About this section

Articles related to Gilles De La Tourette Syndrome:

(show top 50)    (show all 358)
idTitleAuthorsYear
1
Putting the Pieces Together in Gilles de la Tourette Syndrome: Exploring the Link Between Clinical Observations and the Biological Basis of Dysfunction. (27783238)
2017
2
Pathological glutamatergic neurotransmission in Gilles de la Tourette syndrome. (28007998)
2017
3
New Insights into Clinical Characteristics of Gilles de la Tourette Syndrome: Findings in 1032 Patients from a Single German Center. (27672357)
2016
4
Temporal relationship between premonitory urges and tics in Gilles de la Tourette syndrome. (26922503)
2016
5
TS-EUROTRAIN: A European-Wide Investigation and Training Network on the Etiology and Pathophysiology of Gilles de la Tourette Syndrome. (27601976)
2016
6
Deep Brain Stimulation in Gilles de la Tourette Syndrome: What Does the Future Hold? A Cohort of 48 Patients. (26348012)
2016
7
The English Version of the Gilles de la Tourette Syndrome-Quality of Life Scale for Children and Adolescents (C&A-GTS-QOL): A Validation Study in the United Kingdom. (27686095)
2016
8
Health-related quality of life in patients with Gilles de la Tourette syndrome at the transition between adolescence and adulthood. (27457656)
2016
9
Impact of Perceived Stress, Anxiety-Depression and Social Support on Coping Strategies of Parents Having A Child With Gilles de la Tourette Syndrome. (26804511)
2016
10
A preliminary examination of self-concept in older adolescents and young adults with Gilles de la Tourette syndrome. (28017555)
2016
11
Aripiprazole Improves Associated Comorbid Conditions in Addition to Tics in Adult Patients with Gilles de la Tourette Syndrome. (27672358)
2016
12
The effects of Gilles de la Tourette syndrome and other chronic tic disorders on quality of life across the lifespan: a systematic review. (26880181)
2016
13
Gilles de la Tourette syndrome is associated with hypermethylation of the dopamine D2 receptor gene. (27883923)
2016
14
Illusion of agency in patients with Gilles de la Tourette Syndrome. (26963083)
2016
15
The relationship between tics, OC, ADHD and autism symptoms: A cross- disorder symptom analysis in Gilles de la Tourette syndrome patients and family-members. (26826899)
2016
16
Health-related quality of life, anxiety and depression in parents of adolescents with Gilles de la Tourette syndrome: a controlled study. (27942998)
2016
17
Tetrabenazine-induced oculogyric crisis - a rare complication in the treatment of Gilles de la Tourette syndrome. (26955276)
2016
18
Investigation of SNP rs2060546 Immediately Upstream to NTN4 in a Danish Gilles de la Tourette Syndrome Cohort. (27920664)
2016
19
Altered perceptual binding in Gilles de la Tourette syndrome. (27544346)
2016
20
Deep brain stimulation in Gilles de la Tourette syndrome: killing several birds with one stone? (27746910)
2016
21
BDNF and LTP-/LTD-like plasticity of the primary motor cortex in Gilles de la Tourette syndrome. (27900437)
2016
22
The International Deep Brain Stimulation Registry and Database for Gilles de la Tourette Syndrome: How Does It Work? (27199634)
2016
23
Retraction Note to: Association of Catechol-O-methyltransferase val/met polymorphism with cognitive function in Gilles de la Tourette syndrome patients. (26282617)
2015
24
Gilles de la Tourette syndrome is not linked to contactin-associated protein receptor 2 antibodies. (26462472)
2015
25
Cerebellar neurophysiology in Gilles de la Tourette syndrome and its role as a target for therapeutic intervention. (26643291)
2015
26
Association of ADORA1 rs2228079 and ADORA2A rs5751876 Polymorphisms with Gilles de la Tourette Syndrome in the Polish Population. (26317759)
2015
27
Corrections. A personal 35 year perspective on Gilles de la Tourette syndrome: assessment, investigations, and management. (26360068)
2015
28
Association study between CDH2 and Gilles de la Tourette syndrome in a Danish cohort. (26032459)
2015
29
A personal 35 year perspective on Gilles de la Tourette syndrome: prevalence, phenomenology, comorbidities, and coexistent psychopathologies. (26359614)
2015
30
The anarchic brain in action: the contribution of task-based fMRI studies to the understanding of Gilles de la Tourette syndrome. (26402403)
2015
31
Association of AADAC Deletion and Gilles de la Tourette Syndrome in a Large European Cohort. (26444075)
2015
32
Patients with Gilles de la Tourette syndrome have widespread personality differences. (26112450)
2015
33
Altered structure of cortical sulci in gilles de la Tourette syndrome: Further support for abnormal brain development. (25820811)
2015
34
Enhanced habit formation in Gilles de la Tourette syndrome. (26490329)
2015
35
Alterations in structural connectivity may contribute both to the occurrence of tics in Gilles de la Tourette syndrome and to their subsequent control. (25627236)
2015
36
A t(3;9)(q25.1;q34.3) translocation leading to OLFM1 fusion transcripts in Gilles de la Tourette syndrome, OCD and ADHD. (25595337)
2015
37
Irritability symptoms in Gilles de la Tourette syndrome. (25716486)
2015
38
Premonitory Urges in Patients with Gilles de la Tourette Syndrome: An Italian Translation and a 7-Year Follow-up. (26288345)
2015
39
A personal 35 year perspective on Gilles de la Tourette syndrome: assessment, investigations, and management. (26359615)
2015
40
An fMRI investigation of motor control in Gilles de la Tourette Syndrome during imagined and executed movements. (26566185)
2015
41
Temporary deep brain stimulation in Gilles de la Tourette syndrome: A feasible approach? (26290773)
2015
42
Corrections. A personal 35 year perspective on Gilles de la Tourette syndrome: prevalence, phenomenology, comorbidities, and coexistent psychopathologies. (26360067)
2015
43
Structural Connectivity in Gilles de la Tourette Syndrome. (26933567)
2015
44
Gilles de la Tourette syndrome in a cohort of deaf people. (26216703)
2015
45
Narcissistic vulnerability is a common cause for depression in patients with Gilles de la Tourette syndrome. (26548979)
2015
46
Deep Brain Stimulation of the Pallidum Internum for Gilles de la Tourette Syndrome: A Patient-Specific Model-Based Simulation Study of the Electric Field. (25284508)
2014
47
Gilles de la Tourette Syndrome caused by Mycoplasma pneumoniae successfully treated with macrolides. (25153913)
2014
48
Three Cases of Palatal Tics and Gilles De La Tourette Syndrome. (25246300)
2014
49
Association of Catechol-O-methyltransferase val/met polymorphism with cognitive function in Gilles de la Tourette syndrome patients. (25367405)
2014
50
Coprolalia and copropraxia in patients with Gilles de la Tourette syndrome. (24636763)
2014

Variations for Gilles De La Tourette Syndrome

About this section

Clinvar genetic disease variations for Gilles De La Tourette Syndrome:

5
id Gene Variation Type Significance SNP ID Assembly Location
1HDCNM_002112.3(HDC): c.951G> A (p.Trp317Ter)SNVPathogenicrs267606861GRCh37Chr 15, 50544717: 50544717
2SLITRK1NM_052910.2(SLITRK1): c.1264delC (p.Leu422Phefs)deletionPathogenicrs193302861GRCh37Chr 13, 84454379: 84454379
3SLITRK1NM_052910.2(SLITRK1): c.*689G> ASNVPathogenicrs191284403GRCh37Chr 13, 84452863: 84452863

Copy number variations for Gilles De La Tourette Syndrome from CNVD:

6
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
160595118830000092800000Copy numberGRM5Tourette syndrome
2974011617900000Copy numberA2BP1Tourette syndrome
3107550171590000022100000MicrodeletionTourette syndrome
4161233221790000022200000DuplicationCOMTTourette syndrome
52040476105500000114600000Copy numberNKAIN2Tourette syndrome
62180837107400000127100000Copy numberIMMP2LTourette syndrome
72213707143100000147900000Copy numberCNTNAP2Tourette syndrome
82224857152600000155100000Copy numberDPP6Tourette syndrome
9257157X14300000DeletionNLGN4Tourette syndrome

Expression for genes affiliated with Gilles De La Tourette Syndrome

About this section
Search GEO for disease gene expression data for Gilles De La Tourette Syndrome.

Pathways for genes affiliated with Gilles De La Tourette Syndrome

About this section

GO Terms for genes affiliated with Gilles De La Tourette Syndrome

About this section

Cellular components related to Gilles De La Tourette Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1dendritic spineGO:004319710.6COMT, DRD2, DRD4
2axonGO:00304249.8CNTNAP2, COMT, DRD2, HMBS, ROBO3, SLC6A3
3integral component of plasma membraneGO:00058878.6ADRA1A, ADRA2A, DRD2, DRD4, DRD5, HTR3B

Biological processes related to Gilles De La Tourette Syndrome according to GeneCards Suite gene sharing:

(show all 35)
idNameGO IDScoreTop Affiliating Genes
1adenohypophysis developmentGO:002198410.8DRD2, SLC6A3
2adenylate cyclase-inhibiting dopamine receptor signaling pathwayGO:000719510.8DRD2, DRD4
3arachidonic acid secretionGO:005048210.8DRD2, DRD4
4behavioral response to cocaineGO:004814810.8DRD2, DRD4
5catecholamine biosynthetic processGO:004242310.8DBH, HDC
6dopamine receptor signaling pathwayGO:000721210.8DRD2, DRD4
7regulation of dopamine metabolic processGO:004205310.8DRD4, SLC6A3
8prepulse inhibitionGO:006013410.8DRD2, SLC6A3
9negative regulation of protein secretionGO:005070910.8DRD2, DRD4
10fear responseGO:004259610.8DBH, DRD4
11negative regulation of voltage-gated calcium channel activityGO:190138610.8DRD2, DRD4
12positive regulation of dopamine uptake involved in synaptic transmissionGO:005158610.8DRD2, DRD4
13negative regulation of cAMP biosynthetic processGO:003081810.8ADRA2A, DRD4
14phospholipase C-activating dopamine receptor signaling pathwayGO:006015810.7DRD2, DRD5
15modulation of synaptic transmissionGO:005080410.7BTBD9, DRD2
16adult behaviorGO:003053410.7CNTNAP2, DRD2, SLITRK1
17response to histamineGO:003477610.6DRD2, DRD4
18response to iron ionGO:001003910.6DRD2, SLC6A3
19behavioral response to ethanolGO:004814910.6DBH, DRD2, DRD4
20locomotory behaviorGO:000762610.6DBH, DRD2, SLC6A3
21dopamine metabolic processGO:004241710.6COMT, DRD2, DRD4
22negative regulation of adenylate cyclase activityGO:000719410.6ADRA2A, DRD2, DRD4
23dopamine catabolic processGO:004242010.6COMT, DBH, SLC6A3
24norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressureGO:000199410.5ADRA1A, DRD5
25striatum developmentGO:002175610.5CNTNAP2, DRD2
26short-term memoryGO:000761410.5COMT, DRD4
27associative learningGO:000830610.5DBH, DRD2, DRD5
28response to cocaineGO:004222010.5DRD2, DRD5, SLC6A3
29learningGO:000761210.5CNTNAP2, COMT, DRD5
30response to painGO:004826510.5COMT, DBH
31adenylate cyclase-activating adrenergic receptor signaling pathwayGO:007188010.4ADRA1A, ADRA2A, DRD2
32response to amphetamineGO:000197510.3DBH, DRD2, DRD4, DRD5
33synaptic transmission, dopaminergicGO:000196310.2DRD2, DRD4, DRD5
34transmission of nerve impulseGO:001922610.1CNTNAP2, DRD5
35response to drugGO:00424939.8ADRA1A, COMT, DRD2, HMBS, SLC6A3

Molecular functions related to Gilles De La Tourette Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1dopamine neurotransmitter receptor activity, coupled via Gi/GoGO:000159110.6DRD2, DRD4
2dopamine neurotransmitter receptor activity, coupled via GsGO:000158810.6DRD4, DRD5
3dopamine neurotransmitter receptor activityGO:000495210.4DRD2, DRD4, DRD5
4dopamine bindingGO:003524010.2DRD2, DRD4, DRD5, SLC6A3
5drug bindingGO:00081449.9DRD2, DRD4, SLC6A3

Sources for Gilles De La Tourette Syndrome

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet